We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Stem Cells from Fat Tissue Promise Treatment for MS

By LabMedica International staff writers
Posted on 07 May 2009
A preliminary study on the use of stem cells obtained from a patient's own adipose tissue in the treatment of multiple sclerosis (MS) has shown promising results.

Three case studies, described in April 2009 in BioMed Central's open access Journal of Translational Medicine, support additional clinical evaluation of stromal vascular fraction (SVF) cells in MS and other autoimmune conditions. Thomas Ichim, from Medistem, Inc. (Chandler, AZ, USA), and Dr. Boris Minev, from the division of neurosurgery, University of California San Diego (USA; www.ucsd.edu), worked with a team of researchers to demonstrate the possible effectiveness of SVF cells in MS treatment. Dr. Minev said, "All three patients in our study showed dramatic improvement in their condition after the course of SVF therapy. While obviously no conclusions in terms of therapeutic efficacy can be drawn from these reports, this first clinical use of fat stem cells for treatment of MS supports further investigations into this very simple and easily-implementable treatment methodology."

MS is an autoimmune condition, in which the body's own defenses attack nerve cells, resulting in loss of their fatty myelin sheath. The first symptoms typically occur in young adults, most commonly in women. It is believed that SVF cells and other stem cells may be able to treat the condition by limiting the immune reaction and promoting the growth of new myelin. According to Dr. Minev, "None of the presently available MS treatments selectively inhibit the immune attack against the nervous system, nor do they stimulate regeneration of previously damaged tissue. We've shown that SVF cells may fill this therapeutic gap."

Dr. Minev and his colleagues provided the SVF treatment to three patients with MS. The first had suffered frequent painful seizures for the previous three years; after treatment he reported that the seizures had stopped completely and that he had seen significant improvements in his cognition and a reduction of spasticity in his arms and legs.

The second patient reported improvements in his sense of balance and coordination, as well as an improved energy level and mood. The final patient had been diagnosed with MS in 1993. After SVF treatment in 2008, his gait, balance, and coordination improved dramatically over a period of several weeks. According to Dr. Minev, "His condition continued to improve over the next few months and he is currently reporting a continuing improvement and ability to jog, run, and even bicycle."

Related Links:
Medistem
University of California San Diego


New
Gold Member
C-Reactive Protein Reagent
CRP Ultra Wide Range Reagent Kit
Automated Blood Typing System
IH-500 NEXT
New
Sulfidoleukotrienes (sLT) Assay
CAST ELISA
New
Human Immunodeficiency Virus Assay
RealLine HIV Quantitative Kit

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma

New Method Simplifies Preparation of Tumor Genomic DNA Libraries